| Title |
Bevacizumab in the Treatment of Ovarian Cancer
|
|---|---|
| Published in |
Advances in Therapy, August 2012
|
| DOI | 10.1007/s12325-012-0041-9 |
| Pubmed ID | |
| Authors |
Florian Heitz, Philipp Harter, Jana Barinoff, Bianca Beutel, Paevi Kannisto, Jacek P. Grabowski, Julia Heitz, Christian Kurzeder, Andreas du Bois |
| Abstract |
In the past decade there have been many attempts to improve systemic treatment and thus the outcome of patients with ovarian cancer. However, neither the sequential addition of non cross-resistant drugs to standard chemotherapy comprising carboplatin and paclitaxel, nor triplet combination therapies with conventional chemotherapeutic drugs have improved outcomes. Instead, such approaches have led to an increase in the incidence of side effects. We are currently experiencing a shift toward the addition of molecularly targeted and biological anticancer therapies to standard treatment. Vascular endothelial growth factor (VEGF), which improves vitally important tumor vasculature, is secreted by a range of tumors, and a high level of VEGF is known to be an independent risk factor for aggressive disease in ovarian cancer. This finding led to the development in the 1990s of bevacizumab, a humanized monoclonal antibody against VEGF. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| South Africa | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 3% |
| India | 1 | 1% |
| Portugal | 1 | 1% |
| Unknown | 67 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 20% |
| Student > Master | 10 | 14% |
| Student > Bachelor | 8 | 11% |
| Student > Ph. D. Student | 7 | 10% |
| Professor | 6 | 8% |
| Other | 14 | 20% |
| Unknown | 12 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 37% |
| Biochemistry, Genetics and Molecular Biology | 9 | 13% |
| Agricultural and Biological Sciences | 9 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Computer Science | 2 | 3% |
| Other | 8 | 11% |
| Unknown | 12 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 October 2012.
All research outputs
#14,732,278
of 22,675,759 outputs
Outputs from Advances in Therapy
#1,221
of 2,330 outputs
Outputs of similar age
#104,083
of 169,206 outputs
Outputs of similar age from Advances in Therapy
#14
of 23 outputs
Altmetric has tracked 22,675,759 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,330 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 169,206 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.